[Recent findings and advances in treatment of myeloproliferative neoplasms].
Rinsho Ketsueki
; 65(5): 375-384, 2024.
Article
in Ja
| MEDLINE
| ID: mdl-38825516
ABSTRACT
Many novel agents have been developed for BCRABL1-negaive myeloproliferative neoplasms (MPN), namely, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Some of these agents not only achieve hematologic complete response, reduce spleen size, and alleviate constitutional symptoms, but also induce molecular response, which means that they reduce the allele burden of driver gene mutations. These agents also prevent and alleviate fibrosis in bone marrow, which reduces the incidence of thrombotic events and disease progression and might improve prognosis. This article discusses the latest findings and promising treatments, including ongoing clinical trials, in PV, ET, and PMF.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myeloproliferative Disorders
Limits:
Humans
Language:
Ja
Journal:
Rinsho Ketsueki
Year:
2024
Type:
Article